Burrill highlights the new austerity in biopharma; Should AstraZeneca buy out AbbVie?; Cytokinetics raises $60M;

 @FierceBiotech: Check out our live coverage of ‪BIO 2012‬ in Boston. More | Follow @FierceBiotech

 @JohnCFierce: Tesaro sets IPO terms, looks to raise about $81M, with $25M maybe coming from insiders - I'd like to see this one work. More | Follow @JohnCFierce

 @RyanMFierce: Thanks @Millennium_US, Shire, and Biogen for participating on our ‪BIO 2012‬ panel. We drew a crowd and covered a lot. | Follow @RyanMFierce

> Steven Burrill always gets a good crowd to hear his annual review of the biopharma business at BIO. This year his followers were treated to some grim trends, with increasing austerity in Europe helping to create a new environment for developers, who now have to increasingly consider not just the safety and efficacy of new therapies, but also how much they can fetch on the market after an approval. "Whether or not we like it, the Europeans are writing the rules for pharmacoeconomic efficiency," Burrill said, according to a report in the Boston Business Journal. He also noted that the chances of landing an NIH grant for very early stage research projects have shriveled while the average age of a researcher has risen to the late 40s. Story

> Analysts at Liberum Capital have taken stock of AstraZeneca's woes and come up with their idea of an ideal solution: The acquisition of AbbVie, the biopharma arm being spun off from Abbott Laboratories. Report

> Shares of South San Francisco-based Cytokinetics ($CYTK) slid 12% this morning after the biotech announced a financing of $60 million through the sale of shares. Release

Pharma News

 @FiercePharma: Daiichi to take over ‪Ranbaxy‬ unit's marketing in Venezuela, latest 'hybrid biz model' move to make buyout pay off. More | Follow @FiercePharma

> CSL confirms Fluvax manufacturing tied to convulsions in children. News

> Spanish drugmakers hold out their hats to government. More

> Icahn comes back at Forest with 4 board nominees. Story

Medical Devices News 

 @FierceMedDev: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @FierceMedDev

> Exclusive: Allegro Diagnostics is raising a $15M-$20M Series B round. Story

> Expect steady growth for the urological devices market. More

> Bard pours $40M-plus into Puerto Rican device production expansion. News

Drug Delivery News

 @DamianFierce: Drugmakers are rethinking drug delivery methods for multiple sclerosis treatments. Report | Follow @DamianFierce

> Notre Dame's nanoparticles effective against drug-resistant cancer. Story

> Ambrx nabs $303M deal with Merck for 'smart bomb' delivery. Article

> TheStreet: Alkermes should stick to drug delivery. More

> Explosive nanocarriers thwart target cells' defenses. News

Biomarkers News

> Blood test for pancreatic cancer may be possible. Story

> Huntington's disease marker emerges in clinical trial. News

> Biodesix feels the buzz at BIO2012. Article

And Finally… Investigators at North Carolina State University say that gold nanoparticles with a slight positive charge can unravel DNA's double helix, which has implications for gene therapy research. Release

 

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.